$13.06
Today
as of Jul 22, 16:48 ET
Last 30 days
Recent Press Releases & News
Enanta Enters $75 Million At-the-Market Stock Offering Agreement
Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?
Enanta Files Appeal in Ongoing Patent Dispute With Pfizer Over Paxlovid
Overview
52-week range
$6.43
$17
62% of range
Avg surprise (last 3)
+10.8%
Avg reaction (last 2)
+3.0%
100% positive
Latest IV / EM
84%
EM ±19.1% · $13 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 11, 2026 | Mar/2026 | $-0.45 | $-0.46 | +2.2% | +57.5% | +0.8% | earnings |
| Wed Dec 31, 2025 | Dec 2025 | $-0.42 | — | — | — | — | financials |
| Mon Aug 11, 2025 | Jun/2025 | $-0.85 | $-1.25 | +32.0% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-1.06 | $-1.04 | -1.9% | — | +5.3% | earnings |
| Tue Dec 31, 2024 | Dec 2024 | $-1.05 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.07 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.47 | — | — | — | — | financials |
| Sun Dec 31, 2023 | Dec 2023 | $-1.58 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-1.86 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 10, 2026 | Jun/2026 | OTHER | -$0.37 | -$0.85 | +56.5% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-12M | $-11M | — | $-19M | $-25M | $-24M | — | $-24M |
| Net income | $-13M | $-12M | — | $-18M | $-23M | $-22M | — | $-23M |
| EPS (diluted) | $-0.45 | $-0.42 | — | $-0.85 | $-1.06 | $-1.05 | — | $-1.07 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $35M | $37M | $32M | $45M | $60M | $84M | $37M | $36M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $178M | $199M | $204M | $223M | $243M | $268M | $300M | $287M |
| Total assets | $315M | $330M | $281M | $301M | $323M | $349M | $377M | $399M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $198M | $203M | $216M | $222M | $229M | $237M | $248M | $250M |
| Total equity | $117M | $127M | $65M | $79M | $94M | $112M | $129M | $149M |